Javed Mirza Pfizer Inc PFE-N TOP PICK Dec 24, 2024

Acquisitions in oncology weren't enough for the stock. A long-term play. Slightly disappointing on the year, but oncology segment will continue to do well going forward.

It's too low to sell. Collect the dividend and see if we get good news about the Seagen acquisition.

Market's been tough on it. Investing $2B a year on R&D, made some acquisitions. Lots in the pipeline is up in the air. Stock will pop eventually back to its historical $40-45, and then he'll probably cash in. In his income fund, with the yield at 6%.

It has over paid for some M&A. It is a deep value play but needs a catalyst. It has had some management change but recovery is not part of their investment style. They sold about a year and a half ago.

It reports Tuesday. Their anti-cancer drugs still haven't broken up to justify the cost of acquiring them. Good news would pop shares up. Little downside now.

It's cheap, but for a reason. Sees no growth, despite a big acquisition. Consider Merck or Amgen for perhaps more growth.

You'd have thought they'd be hit more by tariffs, as Trump hammers on that many drug components are made overseas. So the market must be thinking tariffs will benefit pharma, to explain why this name is up on such a tremendously down day. Keeping people guessing and on a knife's edge isn't a bug of the current US administration, it's a feature.

His healthcare investments focus on health management like UNH and medical devices.

Thinks dividend is safe, but may be challenged. Spent billions on acquisitions, but hasn't gained much. Not growing. Any boost to bottom line comes from cost cuts. Downhill since Covid, pipeline not strong. Better opportunities in the pharma space, such as MRK. 

Failure in a couple of drugs. Huge research program; they will find new drugs. Outstanding stock to accumulate because, at some point, they're going to announce a new drug and the stock will pop. Yield is close to 7-8%.